**Tables:**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Parameters | Type 2 diabetic patients with obesity | | | | | | | | | p |
| Total | | | Group 1 | | | Group 2 | | |
| Baseline | Metformin  (12 W) | Metformin +  SGLT2 inhibitors  (24 W) | Baseline | Metformin  (12 W) | Metformin + Dapagliflozin (24 W) | Baseline | Metformin  (12 W) | Metformin + Empagliflozin (24 W) |
| RBP4 (μg/mL) | 129.40±9.69 | 129.07±9.24 | 122.93±9.84a | 127.86±9.64 | 128.00±9.12 | 121.36±9.69b | 130.75±9.84 | 130.00±9.54 | 124.31±10.07b |  |
| Change | -0.30 (-0.89, 0.29), -6.16 (-7.07, -5.26) | | | 0.14 (-0.71, 1.00), -6.64 (-8.01, -5.27) | | | -0.75 (-1.65, 0.15), -5.69 (-7.03, -4.35) | | | 0.463 |
| FABP4 (ng/mL) | 57.93±3.34 | 58.01±3.34 | 54.72±3.39a | 57.14±3.13 | 57.17±3.06 | 53.85±3.26b | 58.61±3.46 | 58.75±3.50 | 55.48±3.43b |  |
| Change | 0.08 (-0.18, 0.34), -3.30 (-3.96, -2.63) | | | 0.03 (-0.34, 0.39), -3.32 (-4.18, -2.46) | | | 0.14 (-0.27, 0.55), -3.28 (-4.36, -2.19) | | | 0.200 |
| Visfatin (ng/mL) | 11.98±0.94 | 11.99±0.94 | 10.04±0.99a | 11.91±0.86 | 11.90±0.86 | 9.99±0.92b | 12.04±1.03 | 12.06±1.00 | 10.09±1.07b |  |
| Change | 0.01 (-0.06, 0.07), -1.95 (-2.22, -1.67) | | | -0.01 (-0.11, -0.09), -1.91 (-2.29, -1.54) | | | 0.02 (-0.07, 0.11), -1.98 (-2.41, -1.54) | | | 0.696 |
| Adiponectin (μg/mL) | 6.50±2.38 | 6.51±2.30 | 11.50±2.35a | 6.17±2.21 | 6.17±2.17 | 11.41±2.44b | 6.79±2.54 | 6.81±2.43 | 11.58±2.34b |  |
| Change | 0.00 (-0.12, 0.12), 5.00 (4.58, 5.42) | | | 0.00 (-0.15, 0.15), 5.24 (4.61, 5.86) | | | 0.01 (-0.19, 0.22), 4.77 (4.12, 5.42) | | | 0.580 |
| Data are means ± SD, or 95% CI. p < 0.05 was considered significant.  SGLT2: Sodium glucose cotransporter 2, RBP4: Retinol binding protein 4, FABP4: Fatty acid binding protein 4.  a p < 0.05 (comparison between before treatment and after treatment in all subjects)  b p < 0.05 (comparison between before treatment and after treatment in each group) | | | | | | | | | | |

Table 5: Change from baseline to treatment with metformin, before and after add-on therapy of SGLT2 inhibitors on adipokines in obese type 2 diabetes.